A Randomized, Double-blind, Parallel Group Study to Investigate the Efficacy and Safety of Treatment With Dutasteride (0.5mg) and Tamsulosin (0.4mg), Administered Once Daily for 4 Years, Alone and Combination, on the Improvement of Symptoms and Clinical Outcome in Men With Moderate to Severe Symptomatic Benign Prostatic Hyperplasia
Phase of Trial: Phase III
Latest Information Update: 05 Nov 2016
At a glance
- Drugs Dutasteride (Primary) ; Tamsulosin (Primary)
- Indications Benign prostatic hyperplasia; Lower urinary tract symptoms
- Focus Registrational; Therapeutic Use
- Acronyms CombAT
- Sponsors GlaxoSmithKline
- 18 Feb 2011 Four-year results according to baseline characteristics published in the BJU International.
- 25 Jun 2010 Four-year results according to baseline prostate volume were presented at the 105th Annual Meeting of the American Urological Association.
- 14 Jun 2010 The US FDA has approved dutasteride and tamsulosin fixed-dose combination [Jalyn] for symptomatic BPH in men with an enlarged prostate, based on the 2-year results from this trial, as reported in a media release from GlaxoSmithKline.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History